The efficacy of dual inhibition of PD-L1 and PD-L2 is more effective than anti–PD-1 or PD-L1 alone in various types of cancers that express both PD-L2 and PD-L1, including ovarian cancer (56). The gene discussed is CD274; the disease is cancer.